InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
3
T+90 hit rate
0%
T+90 mean return
-41.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Flynn Karen, Président des Biologiques et CCO. Director active across 5 companies, notably Catalent, Inc.. Cumulatively, 18 reports have been published. Split: 0 buy · 3 sells. Total volume traded: €508k. History available since 26 July 2021. The latest transaction was filed on 22 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations18 total
4,975 sharesOrdinary SharesSEC:0001193125-26-283788:0
1,493 sharesOrdinary SharesSEC:0001193125-26-283788:1
14,970 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0001193125-26-242231:0
7,435 shares0Common StockSEC:0001562180-25-000202:0
20,089 shares0Common Stock, $0.01 par value per share ("Common Stock")SEC:0000950170-24-066037:0
2,947 shares0Common StockSEC:0001562180-24-000232:0
6,993 shares0Common StockSEC:0001596783-23-000153:0
8,083 shares0Common StockSEC:0001562180-23-000102:0
4,149 shares0Common StockSEC:0001596783-22-000169:0
1,066 shares@ US$10.4881.2% of flowCommon StockSEC:0001562180-22-007044:0
245 shares0Common StockSEC:0001596783-22-000142:0
164 shares@ US$16.7918.8% of flowCommon StockSEC:0001562180-22-005558:0
13,227 shares0Common StockSEC:0001562180-22-005091:0
2,472 shares@ US$116.6450.0% of flowCommon StockSEC:0001596783-22-000014:0
2,472 shares@ US$116.6450.0% of flowCommon StockSEC:0001596783-22-000014
1,151 shares0Common StockSEC:0001596783-21-000092
1,151 shares0Common StockSEC:0001596783-21-000092:0
10.75 sharesCommon StockSEC:0001225208-16-023358:0
18 of 18 declarations
About Flynn Karen
Karen Flynn is the President of Biologics and CCO at Catalent, Inc. and Quanterix Corp. She oversees the company's commercial and strategic operations. Her role is crucial in ensuring growth and innovation in the biopharmaceutical sector.
